Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

4.160 +0.020 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 Next >
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
More People are Microdosing Psychedelics to Ease the Challenges of Parenting
Via Investor Brand Network
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in Stifel Virtual CNS Forum
From Compass Pathways plc
Via Business Wire
US Embassy Tells Americans to Desist from Using Ayahuasca in Peru
Via Investor Brand Network
Topics Law Enforcement
Exposures Legal
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
From Compass Pathways plc
Via Business Wire
Washington State Bills Seek to Legalize Psychedelics for Therapeutic Use
Via Investor Brand Network
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Compass Pathways plc
Via Business Wire
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
From Compass Pathways plc
Via Business Wire
Compass Pathways Announces Pricing of Underwritten Offering
From Compass Pathways plc
Via Business Wire
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in December Investor Conferences
From Compass Pathways plc
Via Business Wire
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates
From Compass Pathways plc
Via Business Wire
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
From Compass Pathfinder Limited
Via Business Wire
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Compass Pathways appoints Teri Loxam as Chief Financial Officer
From Compass Pathways
Via GlobeNewswire
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression 
From Compass Pathways
Via GlobeNewswire
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
COMPASS Pathways announces CFO transition
From COMPASS Pathways
Via GlobeNewswire
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Exposures Product Safety
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.